Ginkgo Biloba
Ginkgo has seizure case reports and may counter seizure control.
Recommendation: Avoid ginkgo in epilepsy unless specifically approved by the neurologist.
Prescription ·Strong evidence ·Reviewed May 2026
Levetiracetam extended-release is an antiseizure medication used once daily for focal-onset seizures and other seizure types depending on labeling and clinician judgment. It has minimal hepatic metabolism and few pharmacokinetic interactions, but behavioral adverse effects such as irritability, depression, aggression, or suicidality can be clinically important. Dosing must be adjusted for kidney function.
The bottom line
Evidence rating strong. Most-documented uses: adjunctive treatment of focal-onset seizures, once-daily adherence support compared with immediate-release dosing, low pharmacokinetic interaction burden. 3 sources indexed (2011–2025), with 4 interaction records on file.
Core mechanism
Levetiracetam binds synaptic vesicle protein 2A, modulating neurotransmitter release and reducing neuronal hypersynchrony involved in seizure propagation. It does not meaningfully induce or inhibit cytochrome P450 enzymes. Renal elimination is the major clearance pathway, so reduced kidney function increases exposure.2,3
May be taken with or without food. Extended-release tablets should be swallowed whole and not crushed, chewed, or split.3
Ginkgo has seizure case reports and may counter seizure control.
Recommendation: Avoid ginkgo in epilepsy unless specifically approved by the neurologist.
Melatonin can add to levetiracetam-related somnolence or dizziness.
Recommendation: Use cautiously and monitor next-day alertness.
L-Theanine may have calming effects and could add to levetiracetam-related fatigue or dizziness.
Recommendation: Use cautiously during dose changes and avoid hazardous activities if impaired.
Ashwagandha can be sedating for some patients and may compound levetiracetam CNS effects.
Recommendation: Use cautiously and monitor for sedation, mood changes, or irritability.
Search all 4 interaction records for Levetiracetam Extended-Release →
Numbered references. Citations throughout the page link here.
Consensus review supports monitoring for mood and behavior changes during antiseizure therapy.
Review describes SV2A mechanism, broad antiseizure use, and limited drug-metabolism interactions.
Labeling specifies 1000 mg once-daily initiation, titration to 3000 mg/day, renal adjustment, behavioral warnings, and hypersensitivity contraindication.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.